Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Multifocal Tumefactive Demyelination Mimicking Intracranial Neoplasm.
Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.
The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis.
A randomized controlled phase II trial of riluzole in early multiple sclerosis.
In vivo time-lapse imaging shows dynamic oligodendrocyte progenitor behavior during zebrafish development.
Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci.
IL-17 and GM-CSF Expression Are Antagonistically Regulated by Human T Helper Cells.
CXCR7 Is Involved in Human Oligodendroglial Precursor Cell Maturation.
Prediction of oxygen uptake during walking in ambulatory persons with multiple sclerosis.
Foxp3(+) Treg cells in the inflamed CNS are insensitive to IL-6-driven IL-17 production.
Are changes in gait and balance across the Disease Step Rating Scale in Multiple Sclerosis statistically significant and clinically meaningful?
Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease.
PML in a patient treated with fumaric acid.
Our Products (page shows "Copaxone" as a trade name for glatiramer acetate)
Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)
Clinical experience with repository corticotropin injection in patients with multiple sclerosis experiencing mood changes with intravenous methylprednisolone: a case series.
The Charcot Lecture | Beating MS: A story of B cells, with twists and turns.
Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS.
U.S. Patent Office Declares an Interference Between Forward Pharma and Biogen Regarding the Treatment of Multiple Sclerosis With 480 mg Daily Dose of DMF, the Active Ingredient in Tecfidera(R)
Quantifying brain volumes for Multiple Sclerosis patients follow-up in clinical practice - comparison of 1.5 and 3 Tesla magnetic resonance imaging.
Astrocyte-derived lactosylceramide implicated in multiple sclerosis.
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.
Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
Mitoxantrone: benefits and risks in multiple sclerosis patients.
Nanoparticle transport across the blood brain barrier.

Pages